Microglial-associated responses to comorbid amyloid pathology and hyperhomocysteinemia in an aged knock-in mouse model of Alzheimer’s disease

[1]  D. Wilcock,et al.  Time course of neuropathological events in hyperhomocysteinemic amyloid depositing mice reveals early neuroinflammatory changes that precede amyloid changes and cerebrovascular events , 2019, Journal of Neuroinflammation.

[2]  Anne-Laure Hemonnot,et al.  Microglia in Alzheimer Disease: Well-Known Targets and New Opportunities , 2019, Front. Aging Neurosci..

[3]  Chao Zhang,et al.  Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model , 2019, Nature Communications.

[4]  D. Wilcock,et al.  Blood Flow Deficits and Cerebrovascular Changes in a Dietary Model of Hyperhomocysteinemia , 2019, ASN neuro.

[5]  Christoph Preuss,et al.  Enhancing face validity of mouse models of Alzheimer’s disease with natural genetic variation , 2019, PLoS genetics.

[6]  T. Hortobágyi,et al.  Microglia monitor and protect neuronal function via specialized somatic purinergic junctions , 2019, bioRxiv.

[7]  John X. Morris,et al.  Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction , 2018, Nature Medicine.

[8]  D. Wilcock,et al.  Hyperhomocysteinemia as a Risk Factor for Vascular Contributions to Cognitive Impairment and Dementia , 2018, Front. Aging Neurosci..

[9]  Mark T. W. Ebbert,et al.  Microglial translational profiling reveals a convergent APOE pathway from aging, amyloid, and tau , 2018, The Journal of experimental medicine.

[10]  A. Paetau,et al.  CAIDE Dementia Risk Score, Alzheimer and cerebrovascular pathology: a population‐based autopsy study , 2018, Journal of internal medicine.

[11]  D. Holtzman,et al.  ApoE facilitates the microglial response to amyloid plaque pathology , 2018, The Journal of experimental medicine.

[12]  A. Aguzzi,et al.  Lymphocyte activation gene 3 (Lag3) expression is increased in prion infections but does not modify disease progression , 2018, Scientific Reports.

[13]  L. Rajendran,et al.  Microglia-Mediated Synapse Loss in Alzheimer's Disease , 2018, The Journal of Neuroscience.

[14]  F. LaFerla,et al.  Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer’s disease , 2018, Molecular Neurodegeneration.

[15]  M. Fenech,et al.  Homocysteine and Dementia: An International Consensus Statement , 2018, Journal of Alzheimer's disease : JAD.

[16]  D. Wilcock,et al.  Hyperhomocysteinemia-Induced Gene Expression Changes in the Cell Types of the Brain , 2017, ASN neuro.

[17]  Markus Glatzel,et al.  The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. , 2017, Immunity.

[18]  Guowei Huang,et al.  Homocysteine exaggerates microglia activation and neuroinflammation through microglia localized STAT3 overactivation following ischemic stroke , 2017, Journal of Neuroinflammation.

[19]  K. Langa,et al.  A Comparison of the Prevalence of Dementia in the United States in 2000 and 2012 , 2017, JAMA internal medicine.

[20]  I. Amit,et al.  A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease , 2017, Cell.

[21]  S. Merali,et al.  Five lipoxygenase hypomethylation mediates the homocysteine effect on Alzheimer’s phenotype , 2017, Scientific Reports.

[22]  D. Wilcock,et al.  Time-course of glial changes in the hyperhomocysteinemia model of vascular cognitive impairment and dementia (VCID) , 2017, Neuroscience.

[23]  B. Becher,et al.  Sall1 is a transcriptional regulator defining microglia identity and function , 2016, Nature Immunology.

[24]  E. Hol,et al.  Transcriptional profiling of CD11c-positive microglia accumulating around amyloid plaques in a mouse model for Alzheimer's disease. , 2016, Biochimica et biophysica acta.

[25]  K. Blennow,et al.  Beneficial effects of increased lysozyme levels in Alzheimer's disease modelled in Drosophila melanogaster , 2016, The FEBS journal.

[26]  Ho Chul Kang,et al.  Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3 , 2016, Science.

[27]  Ying Feng,et al.  Sex differences between APPswePS1dE9 mice in A-beta accumulation and pancreatic islet function during the development of Alzheimer’s disease , 2016, Laboratory animals.

[28]  A. Smith,et al.  Homocysteine, B Vitamins, and Cognitive Impairment. , 2016, Annual review of nutrition.

[29]  S. Strickland,et al.  Hyperhomocysteinemia exacerbates Alzheimer's disease pathology by way of the β‐amyloid fibrinogen interaction , 2016, Journal of thrombosis and haemostasis : JTH.

[30]  M. Mehler,et al.  Emerging Roles for CSF-1 Receptor and its Ligands in the Nervous System , 2016, Trends in Neurosciences.

[31]  J. Eilers,et al.  Neurons exhibit Lyz2 promoter activity in vivo: Implications for using LysM‐Cre mice in myeloid cell research , 2016, European journal of immunology.

[32]  V. Bianchi.  Role of nutrition on anemia in elderly. , 2016, Clinical nutrition ESPEN.

[33]  Yan Ren,et al.  Low-Dose Homocystine Enhances Proliferation and Migration of Bv2 Microglia Cells , 2016, Cellular and Molecular Neurobiology.

[34]  K. Andersen,et al.  Figure 2 , 2016, Organic Photoreceptors for Imaging Systems.

[35]  R. Ransohoff,et al.  TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models , 2015, The Journal of experimental medicine.

[36]  D. Praticò,et al.  High levels of homocysteine results in cerebral amyloid angiopathy in mice. , 2014, Journal of Alzheimer's disease : JAD.

[37]  D. Wilcock,et al.  β-amyloid deposition is shifted to the vasculature and memory impairment is exacerbated when hyperhomocysteinemia is induced in APP/PS1 transgenic mice , 2014, Alzheimer's Research & Therapy.

[38]  S. Itohara,et al.  Single App knock-in mouse models of Alzheimer's disease , 2014, Nature Neuroscience.

[39]  S. Gygi,et al.  Identification of a Unique TGF-β Dependent Molecular and Functional Signature in Microglia , 2013, Nature Neuroscience.

[40]  A. Paetau,et al.  Plasma homocysteine, Alzheimer and cerebrovascular pathology: a population-based autopsy study. , 2013, Brain : a journal of neurology.

[41]  Charles D. Smith,et al.  Induction of Hyperhomocysteinemia Models Vascular Dementia by Induction of Cerebral Microhemorrhages and Neuroinflammation , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[42]  Janna H. Neltner,et al.  Early Stage Drug Treatment That Normalizes Proinflammatory Cytokine Production Attenuates Synaptic Dysfunction in a Mouse Model That Exhibits Age-Dependent Progression of Alzheimer's Disease-Related Pathology , 2012, The Journal of Neuroscience.

[43]  R. Collins,et al.  Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. , 2010, Archives of internal medicine.

[44]  R. Prediger,et al.  Role of the macrophage inflammatory protein-1alpha/CC chemokine receptor 5 signaling pathway in the neuroinflammatory response and cognitive deficits induced by beta-amyloid peptide. , 2009, The American journal of pathology.

[45]  S. Lindquist,et al.  Amyloid deposits: Protection against toxic protein species? , 2009, Cell cycle.

[46]  David L. Williams,et al.  β-Glucan Activates Microglia without Inducing Cytokine Production in Dectin-1-Dependent Manner , 2008, The Journal of Immunology.

[47]  R. Mayeux,et al.  Relation of Plasma Homocysteine to Plasma Amyloid Beta Levels , 2007, Neurochemical Research.

[48]  R. Obeid,et al.  Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia , 2006, FEBS letters.

[49]  J. Growdon,et al.  Association of homocysteine with plasma amyloid β protein in aging and neurodegenerative disease , 2005, Neurology.

[50]  Farzaneh A. Sorond,et al.  The role of homocysteine in multisystem age-related problems: a systematic review. , 2005, The journals of gerontology. Series A, Biological sciences and medical sciences.

[51]  J. Nadeau,et al.  Homocysteine levels in A/J and C57BL/6J mice: genetic, diet, gender, and parental effects. , 2005, Physiological genomics.

[52]  L. Cámera,et al.  Prevalence of hyperhomocysteinemia in an elderly population. , 2002, American journal of hypertension.

[53]  B. Strooper,et al.  FAD mutant PS-1 gene-targeted mice: increased Aβ42 and Aβ deposition without APP overproduction , 2002, Neurobiology of Aging.

[54]  M. Mattson,et al.  Folic Acid Deficiency and Homocysteine Impair DNA Repair in Hippocampal Neurons and Sensitize Them to Amyloid Toxicity in Experimental Models of Alzheimer's Disease , 2002, The Journal of Neuroscience.

[55]  P. Wilson,et al.  The effect of folic acid fortification on plasma folate and total homocysteine concentrations. , 1999, The New England journal of medicine.

[56]  S. Vollset,et al.  Major lifestyle determinants of plasma total homocysteine distribution: the Hordaland Homocysteine Study. , 1998, The American journal of clinical nutrition.

[57]  P. Wilson,et al.  Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. , 1993, JAMA.

[58]  Peng Liu,et al.  Quantitative Comparison of Dense-Core Amyloid Plaque Accumulation in Amyloid-β Protein Precursor Transgenic Mice. , 2017, Journal of Alzheimer's disease : JAD.

[59]  David C. Steffens,et al.  Prevalence of Dementia in the United States , 2007 .

[60]  P. Grammas,et al.  Expression of macrophage inflammatory protein 1-alpha is elevated in Alzheimer's vessels and is regulated by oxidative stress. , 2007, Journal of Alzheimer's disease : JAD.

[61]  MD M.C. Irizarry,et al.  Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease. , 2005, Neurology.

[62]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[63]  B. de Strooper,et al.  FAD mutant PS-1 gene-targeted mice: increased A beta 42 and A beta deposition without APP overproduction. , 2002, Neurobiology of aging.

[64]  R. Wolfe,et al.  Homocysteine metabolism. , 1999, Annual review of nutrition.

[65]  E. Boddeke,et al.  Aspects of the Microglia Transcriptome , 2022 .